Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05995496 · ClinicalTrials.gov registry record · NA
Changes in Inhibition and Valuation After Eating
A NA study of Bulimia Nervosa, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT05995496: Recruiting NA study of Bulimia Nervosa, sponsored by Icahn School of Medicine at Mount Sinai.
NCT05995496 is a NA study of Bulimia Nervosa that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 150 participants, below the 1,732-participant average among 23 other Bulimia Nervosa trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05995496, a NA study of Bulimia Nervosa, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
An impaired ability to exert control has been implicated in bulimia nervosa (BN), but this impairment may not represent a stable trait or be the most effective focus for treatment. This project aims to understand how predictions and value-based decisions about control may be abnormally influenced by eating in individuals with BN, thereby maintaining cycles of binge eating, purging, and restriction.
Primary Outcome
Blood oxygen level dependent (BOLD) signal in frontostriatal brain circuitry associated with inhibitory control prediction errors
Conditions Studied
Interventions
- OTHER Fasting state
- OTHER Fed state
- OTHER Magnetic Resonance Imaging
Study Locations (1)
New York
- Center of Excellence in Eating and Weight Disorders at the Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2023-12-12 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What NCT05995496 shows while recruiting
NCT05995496 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 1,732-participant average among 23 other Bulimia Nervosa trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Bulimia Nervosa appearing as the primary indexed condition, and to 3 interventions - of which Fasting state is the first listed.
NCT05995496 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05995496 about?
NCT05995496 is a clinical study titled "Changes in Inhibition and Valuation After Eating". An impaired ability to exert control has been implicated in bulimia nervosa (BN), but this impairment may not represent a stable trait or be the most effective focus for treatment. This project aims to understand how predictions and value-based decisions about control may be abnormally influenced by...
What is the current status of trial NCT05995496?
This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2023-12-12. Estimated completion is 2027-12-31.
What conditions does trial NCT05995496 study?
This clinical trial studies the following conditions: Bulimia Nervosa.
What interventions are being tested in trial NCT05995496?
The interventions under investigation include: Fasting state (OTHER), Fed state (OTHER), Magnetic Resonance Imaging (OTHER).
Who is sponsoring clinical trial NCT05995496?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05995496 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bulimia Nervosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05995496's enrollment target sits among peer trials
150 6th of 23 higher than 18 of 23 other Bulimia Nervosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bulimia Nervosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Therapeutic Ketogenic Diet in Anorexia Nervosa
RECRUITING · NA
-
Targeting Social Function in Anxiety and Eating Disorders
RECRUITING · NA
-
Developing an Artificial Intelligence (AI) Chatbot for Adolescents and Young Adults With Eating Disorders
RECRUITING · NA
-
Neurofeedback During Eating for Bulimia Nervosa
RECRUITING · NA
-
Building an Equitable and Accessible System of Eating Disorder Care for VA, DoD, and Underrepresented Americans
RECRUITING · NA
-
Optimizing Digital Health Technology Interventions to Increase Skill Acquisition and Utilization
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI